Drugs / arabinoside
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT02042690 Comparator | Jul 2014 → Feb 2018 | acute lymphoblastic leukemia | Peking University | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | arabinoside | “Drug:arabinoside 2-3g/m2,q12h, d2-3, IV, used in cycle 1,3,5” NCT02042690 ↗ |
| Route | Intravenous | “arabinoside 2-3g/m2,q12h, d2-3, IV” NCT02042690 ↗ |